# OGSIVEO® (nirogacestat) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nirogacestat

> The FDA approved OGSIVEO® (nirogacestat), sponsored by Immunome Inc. (IMNM), on Nov 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | OGSIVEO® (nirogacestat) |
| Codes |  |
| Sponsor | Immunome Inc. (IMNM) https://sec-api.dev/companies/imnm/catalysts |
| Indications |  |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### Nov 2023: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2024-11-13, last confirmed 2025-11-06.
- SEC Form 10-Q (accession 0001193125-25-269603): "With respect to varegacestat, we expect to compete with companies advancing treatments for desmoid tumors, including SpringWorks Therapeutics, Inc. In November 2023, SpringWorks received FDA approval for its oral gamma secretase inhibitor, OGSIVEO® (nirogacestat), for the treatment of adult patients with progressing tumors who require systemic treatment." https://www.sec.gov/Archives/edgar/data/1472012/000119312525269603/imnm-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104035): "With respect to varegacestat, we expect to compete with companies advancing treatments for desmoid tumors, including SpringWorks Therapeutics, Inc. In November 2023, SpringWorks received FDA approval for its oral gamma secretase inhibitor, OGSIVEO® (nirogacestat), for the treatment of adult patients with progressing tumors who require systemic treatment." https://www.sec.gov/Archives/edgar/data/1472012/000095017025104035/imnm-20250630.htm
- SEC Form 10-Q (accession 0001558370-25-007382): "With respect to varegacestat, we expect to compete with companies advancing treatments for desmoid tumors, including SpringWorks Therapeutics, Inc. In November 2023, SpringWorks received FDA approval for its oral gamma secretase inhibitor, OGSIVEO® (nirogacestat), for the treatment of adult patients with progressing tumors who require systemic treatment." https://www.sec.gov/Archives/edgar/data/1472012/000155837025007382/tmb-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-003302): "With respect to varegacestat, we expect to compete with companies advancing treatments for desmoid tumors, including, but not limited to, SpringWorks Therapeutics, Inc. In November 2023, Springworks received FDA approval for its oral gamma secretase inhibitor, OGSIVEO® (nirogacestat), for the treatment of adult patients with progressing desmoid tumors who require systemic treatment." https://www.sec.gov/Archives/edgar/data/1472012/000155837025003302/tmb-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003302): "With respect to varegacestat, we expect to compete with companies advancing treatments for desmoid tumors, including SpringWorks Therapeutics, Inc. In November 2023, Springworks received FDA approval for its oral gamma secretase inhibitor, OGSIVEO® (nirogacestat), for the treatment of adult patients with progressing tumors who require systemic treatment." https://www.sec.gov/Archives/edgar/data/1472012/000155837025003302/tmb-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015524): "With respect to AL102, we expect to compete with companies advancing treatments for desmoid tumors, including SpringWorks Therapeutics, Inc. In November 2023, Springworks received FDA approval for its oral gamma secretase inhibitor, OGSIVEO® (nirogacestat), for the treatment of adult patients with progressing tumors who require systemic treatment." https://www.sec.gov/Archives/edgar/data/1472012/000155837024015524/tmb-20240930x10q.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nirogacestat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OGSIVEO® (nirogacestat) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nirogacestat

```bibtex
@misc{secapidev_pdufa_nirogacestat_20261116,
  title        = {OGSIVEO® (nirogacestat) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nirogacestat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nirogacestat_20261116","title":"OGSIVEO® (nirogacestat) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nirogacestat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
